More Deals Like Loxo On The Cards As Bayer Ups Ante In Oncology
Bayer's head of pharma Dieter Weinand chats to Scrip on the sidelines of the company's 2017 annual results conference in Leverkusen, Germany, about putting more skin in the game this time around as the second wave of immuno-oncology innovation spills into the market.
You may also be interested in...
The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET.
Keeping Track: Submissions Galore, Blincyto Supplemental Approval, And Priority Review For Opdivo/Yervoy Combo
The latest drug development news and highlights from our US FDA Performance Tracker.
If companies meet their publicly stated NDA filing targets, at least four breakthrough-designated therapies will arrive at US FDA in March.